<DOC>
	<DOC>NCT01584206</DOC>
	<brief_summary>Ezetimibe has become the treatment choice for patients with sitosterolemia. Ezetimibe is an inhibitor of cholesterol absorption from the gastrointestinal tract. The purpose of this study is to determine if ezetimibe improves whole body plant sterol and cholesterol homeostasis.</brief_summary>
	<brief_title>Sitosterolemia Metabolism</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Intestinal Diseases</mesh_term>
	<mesh_term>Lipid Metabolism, Inborn Errors</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<criteria>confirmed diagnosis of homozygous sitosterolemia as established by genotyping and clinical parameters pregnant intellectual disability major infectious diseases immunodeficiency cancer renal failure diabetes</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Sitosterolemia</keyword>
	<keyword>Ezetimibe</keyword>
	<keyword>Plant sterol</keyword>
	<keyword>Cholesterol</keyword>
</DOC>